|By Marketwired .||
|March 14, 2014 05:00 PM EDT||
AURORA, ON -- (Marketwired) -- 03/14/14 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and six-month periods ended January 31, 2014 and 2013.
HIGHLIGHTS FOR THE PERIOD
- On October 15, 2013, the Company completed an interim review of data collected to date for its European Phase I/II clinical study of L-DOS47. Subsequent to the completion of the interim review, on February 18, 2014, the Company announced the start of screening of patients in cohort 7. See "L-DOS47" below under the heading "Research and Development Update".
- At the Company's annual general and special meeting of shareholders ("AGM") held on December 18, 2013, Messrs. Yvon Bastien, Slawomir Majewski, Marek Orlowski, Sven Rohmann, Robert A. Verhagen, Stacy L. Wills and Slawomir Ludwikowski were elected as directors of the Company. In the case of Mr. Ludwikowski, a majority of the votes represented by proxy were withheld from voting for and, in accordance with the Company's majority voting policy, Mr. Ludwikowski was required to submit his resignation to the Board of Directors ("Board") for the Board's consideration. Subsequent to the end of the fiscal quarter, Mr. Ludwikowski tendered his resignation to the Board, which the Board accepted on March 7, 2014. Mr. Mario Gobbo resigned from the Board prior to the AGM.
- On January 10, 2014, the Company announced Marek Orlowski, a member of the Board had purchased 1,000,000 previously issued and outstanding shares of the Company.
- On December 6, 2013, the Company announced the termination of John Docherty, the Company's President and Chief Operating Officer.
- On November 4, 2013, the Company announced the closing of a private placement for net proceeds of $4,672,000. The terms of the private placement are for the purchase of common shares at $1.15 per share and include one warrant per share at an exercise price of $1.61 with an expiry of five years from the date of issue.
RESEARCH AND DEVELOPMENT UPDATE
On May 14, 2012, the Company commenced clinical site initiations and patient recruitment activities for its European Phase I/II clinical study of L-DOS47 in Poland. Since the dosing of the first patient in Cohort 1 on October 23, 2012, the Company remains on target to achieve its milestone of completing Cohort 8 of the Phase I component of the European Phase I/II clinical study by the summer of 2014. As previously disclosed, the total number of patients to be enrolled in the study will depend on how many escalating dose levels are required to reach maximum tolerated dose ("MTD"). The Company originally estimated that MTD would be reached after enrolling eight cohorts of three patients. Management also originally assumed that there would be two dose limiting toxicity events requiring a further six patients to be enrolled, for a total of up to 30 patients by the time the study dosed patients in Cohort 8.
On October 15, 2013, the Company announced the completion of an interim data review of the first four cohorts for this study. The release stated that L-DOS47 was well tolerated for all patients treated within all cohorts. None of the treatment related adverse events reported to date has met the definition of a dose-limiting toxicity. Adverse events reported as of that date are those normally expected for the population under study.
As of March 7, 2014, a total of 21 patients had been dosed in the Phase I component of the study. Based on the latest patient enrollment rates, the Company still expects to complete the enrollment of Cohort 8 of the Phase I component of this study by the summer of 2014. The Company has initiated a protocol amendment that would allow the Company to continue dose escalation for the Phase I component of the study beyond Cohort 8 in the event MTD is not reached by the end of Cohort 8, as originally estimated. Without regulatory approval for the protocol amendment, the Company will not be able to enroll patients beyond Cohort 8.
The Company continues to re-evaluate the U.S. Phase I protocol previously approved by the U.S. Food and Drug Administration ("FDA") and is now developing an investigational new drug ("IND") application for approval by the FDA and commencement of a study for an L-DOS47 Phase I, open label, dose escalation study in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV, recurrent or metastatic non-squamous non-small cell lung cancer ("NSCLC"). In addition, the Company is also developing a new clinical trial application ("CTA") in Canada for approval by Health Canada and commencement of a Phase I study for L-DOS47 in combination with the chemotherapy drug vinorelbine in patients with metastatic NSCLC and metastatic breast cancer.
The Company's cash position as at January 31, 2014 of $4,386,000 is not sufficient to see the entire European Phase I/II clinical study in Poland, nor any part of the U.S. Phase I and Canadian Phase I study, if either or both is approved by regulators, through to completion. The Company has previously disclosed that it expected to have sufficient cash to complete the Phase I portion of the European clinical study, provided the Company did not experience any unforeseen challenges and expenditures. The Company is currently dosing patients in Cohort 7. The Company originally estimated that the Phase I component of this study would enroll eight cohorts, as this was the number of cohorts estimated to be required to reach MTD. However, in the event the Company does receive regulatory approval for the protocol amendment but does not reach MTD at Cohort 8 as originally estimated, the Company will not have sufficient funds to complete the European Phase I trial for L-DOS47 in Poland.
Topical Interferon Alpha-2b
After agreeing to terminate the contractual arrangement with Merck Sharp & Dohme Corp ("Merck"), the Company's primary and ongoing focus, as it relates to the Topical Interferon Alpha-2b program, has been on sourcing and qualifying alternative interferon alpha-2b raw material samples, and finding suitable strategic partner(s) who would be willing to license or acquire the product and supports the remaining development costs through to commercial launch. As a result, the Company has hired an outside consultant to assist it in finding a suitable strategic partner(s).
To date, the Company has completed preliminary quality testing, comparing alternate raw material samples to its approved drug substance specification and a potential new supplier of the interferon alpha-2b raw material necessary to formulate the product candidate has been identified. However, further quality testing and evaluation of this material and its supplier, as well as negotiation of supply terms acceptable to the Company and receipt of necessary regulatory approvals will be necessary before the Company will be in a position to definitively verify raw material comparability with the interferon alpha-2b originally supplied by Merck.
The continuation of the Topical Interferon Alpha-2b program more generally is dependent on a strategic partner(s) providing additional funding.
The Company recorded a net loss and total comprehensive loss of $2,632,000 and $4,769,000, respectively for the three and six-month periods ended January 31, 2014 for a loss per common share of $0.04 and $0.07, respectively. For the comparative three and six-month periods ended January 31, 2013, the Company recorded net income and total comprehensive income of $4,669,000 and $2,592,000, respectively for earnings per common share of $0.07 and $0.04.
Included in net income and total comprehensive income for the three and six-month periods ended January 31, 2013 is a gain on sale from discontinued operations of $6,083,000. On January 25, 2013, the Company announced the sale of its distribution business in Canada.
Excluding both the gain on sale and net income and total comprehensive income from discontinued operations, the Company recorded a net loss and total comprehensive loss from continuing operations of $1,726,000 and $4,126,000, respectively for the three and six-month periods ended January 31, 2013 for a loss per common share of $0.03 and $0.06, respectively.
Research and development
Research and development costs totalled $1,649,000 and $2,981,000, respectively for the three and six-month periods ended January 31, 2014. For the three and six month periods ended January 31, 2013, research and development costs totalled $1,049,000 and $2,657,000, respectively.
L-DOS47 research and development expenses for the three and six-month periods ended January 31, 2014 totalled $556,000 and $1,205,000, respectively ($586,000 and $1,408,000 respectively for the three and six-month periods ended January 31, 2013). L-DOS47 research and development expenditures relate primarily to expenditures associated with the ongoing European Phase I/II clinical study in Poland, costs incurred in the current fiscal quarter associated with the preparation of an IND application with the FDA and ongoing overhead costs in support of the L-DOS47 drug program.
Topical Interferon Alpha-2b research and development expenses for the three and six-month periods ended January 31, 2014 totalled $123,000 and $238,000, respectively ($99,000 and $512,000 respectively for the three and six-month periods ended January 31, 2013). Beginning in June 2012, the Company initiated a downsizing of the staff in the Saskatoon laboratory. The Company further downsized staffing levels at its Saskatoon laboratory in October 2012, including a decision that resulted in the closure of the Saskatoon laboratory at the end of November 2012. Costs associated with the downsizing were charged in fiscal 2013. The Company has now limited its ongoing activities with respect to its Topical Interferon Alpha-2b program to sourcing and qualifying alternative interferon alpha-2b raw material samples, strengthening the BiPhasix patent portfolio and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs.
Corporate research and development expenses for the three and six-month periods ended January 31, 2014 totalled $745,000 and $1,026,000 respectively ($223,000 and $450,000 respectively for the three and six-month periods ended January 31, 2013). Included in corporate research and development expenses for the three and six-month period ended January 31, 2014 is a one-time payout of $500,000 related to a severance payment.
Trademark and patent related expenses for the three and six-month periods ended January 31, 2014 totalled $153,000 and $378,000, respectively ($15,000 and $25,000 respectively for the three and six-month periods ended January 31, 2013). The increased costs relate to the Company's efforts to strengthen the DOS47 and BiPhasix patent portfolios.
Operating, general and administration
Operating, general and administration expenses for the three and six-month periods ended January 31, 2014 totalled $1,011,000 and $1,837,000, respectively ($704,000 and $1,468,000 respectively for the three and six-month periods ended January 31, 2013). Higher operating, general and administration expenses for both the three and six-month periods ended January 31, 2014 and 2013 reflect higher legal fees, consulting fees and investor relations activities.
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash reserves of $4,386,000 as at January 31, 2014 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiatives through to completion. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be of the utmost importance.
The Company's condensed unaudited interim consolidated statement of financial position as at January 31, 2014 and July 31, 2013 are summarized below:
Consolidated Statement of Financial Position (thousand $) January 31 July 31 2014 2013 ----------------- ----------------- Non current assets 576 677 Current assets: Prepaid expenses 208 139 Accounts receivable 348 559 Cash 4,386 4,493 ----------------- ----------------- 4,942 5,191 ----------------- ----------------- Total assets 5,518 5,868 ================= ================= Shareholders' equity 5,004 4,920 Current liabilities: Deferred lease credit 10 23 Accrued liabilities 286 621 Accounts payable 218 304 ----------------- ----------------- 514 948 ----------------- ----------------- Total liabilities & shareholders equity 5,518 5,868 ================= =================
The Company's condensed unaudited interim consolidated statement of net loss and comprehensive loss for the three and six-month periods ending January 31, 2014 and 2013 and the condensed unaudited interim consolidated statement of cash flows for the three and six-month periods ending January 31, 2014 and 2013 are summarized below:
Consolidated Statements of Net Loss and Comprehensive Loss (thousand $, except for per share data) For the three-month For the six-month periods ended periods ended ------------------- ------------------- Jan-31 Jan-31 Jan-31 Jan-31 2014 2013 2014 2013 --------- --------- --------- --------- Expenses: Research and development 1,649 1,049 2,981 2,657 Operating, general & administration 1,011 704 1,837 1,468 (Gain) on disposal of property, plant, equipment - (18) - (18) --------- --------- --------- --------- Results from operating activities before finance items (2,660) (1,735) (4,818) (4,107) Finance items 28 9 49 (19) --------- --------- --------- --------- Loss and total comprehensive loss from continuing operations (2,632) (1,726) (4,769) (4,126) Net income and total comprehensive income from discontinued operations - 312 - 635 Gain from sale of discontinued operation - 6,083 - 6,083 --------- --------- --------- --------- Net income (loss) and total comprehensive income (loss) (2,632) 4,669 (4,769) 2,592 ========= ========= ========= ========= Loss per share from continuing operations * $ (0.04) $ (0.03) $ (0.07) $ (0.06) Income per share from discontinued operations * $ - $ 0.01 $ - $ 0.01 Total loss per common share * $ (0.04) $ 0.07 $ (0.07) $ 0.04 * Figures are for both basic and fully diluted Consolidated Statements of Cash Flows (thousand $) (thousand $) For the three-month For the six-month periods ended periods ended -------------------- -------------------- Jan-31 Jan-31 Jan-31 Jan-31 2014 2013 2014 2013 --------- --------- --------- --------- Cash provided by (used in): Net loss and total comprehensive loss from continuing operations (2,632) (1,726) (4,769) (4,126) Items not involving cash: Depreciation of property, plant and equipment 50 103 104 206 Deferred lease credit (7) (7) (13) (13) Stock-based compensation 153 76 181 172 Foreign exchange loss (19) (7) (35) 27 (Gain) on disposal of property, plant, equipment - (18) - (18) --------- --------- --------- --------- (2,455) (1,579) (4,532) (3,752) Changes in non-cash working capital (329) (375) (279) (337) --------- --------- --------- --------- Operating activities (2,784) (1,954) (4,811) (4,089) Financing activities 4,672 - 4,672 - Investing activities (3) 17 (3) 4 Effect of exchange rate changes on cash 19 7 35 (27) --------- --------- --------- --------- Net decrease in cash from continuing operations 1,904 (1,930) (107) (4,112) Net increase in cash from discontinued operations - 7,095 - 7,728 Cash beginning of the year 2,482 3,313 4,493 4,862 --------- --------- --------- --------- Cash end of the year 4,386 8,478 4,386 8,478 ========= ========= ========= =========
The Company's condensed unaudited interim consolidated financial statements and management's discussion and analysis are being filed under the Company's profile on SEDAR at www.sedar.com, as well as on the Company's website at www.helixbiopharma.com. Shareholders have the ability to receive a hard copy of the Company's unaudited condensed interim consolidated financial statements free of charge upon request at the address below.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47 and Topical Interferon Alpha-2b, including the sourcing and qualifying of alternative raw material samples, strengthening the BiPhasix patent portfolio and finding suitable strategic partners and other information in future periods.
Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for Topical Interferon Alpha-2b, DOS47 and L-DOS47; (iv) the Company's European Phase I/II clinical trials for L-DOS47 in Poland including the number of cohorts required to reach MTD and the Company's potential protocol amendment in connection with this trial; (v) the Company's planned future U.S. Phase I clinical trial for L-DOS47 and the Company's proposed IND and CTA applications; and (vi) future expenditures, the insufficiency of the Company's current cash resources and the need for financing and cost-cutting and/or cost-deferral measures and future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "2014", "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47 and Topical Interferon Alpha-2b (low-grade cervical lesions); that sufficient financing will be obtained in a timely manner to allow the Company to continue operations; the success of the Company's proposed IND and CTA applications and the cost and timeline for reaching MTD in the Company's European Phase I/II clinical trial for L-DOS47 in Poland and/or that the Company's proposed protocol amendments for this study are accepted on a timeline and on terms satisfactory to the Company; the timely provision of services and supplies, including Interferon alpha-2b raw materials, or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support.
The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix's Annual Report, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
The IoT has the potential to create a renaissance of manufacturing in the US and elsewhere. In his session at 18th Cloud Expo, Florent Solt, CTO and chief architect of Netvibes, will discuss how the expected exponential increase in the amount of data that will be processed, transported, stored, and accessed means there will be a huge demand for smart technologies to deliver it. Florent Solt is the CTO and chief architect of Netvibes. Prior to joining Netvibes in 2007, he co-founded Rift Technol...
May. 1, 2016 11:00 PM EDT Reads: 1,584
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
May. 1, 2016 08:00 PM EDT Reads: 1,844
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
May. 1, 2016 07:00 PM EDT Reads: 739
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
May. 1, 2016 06:00 PM EDT Reads: 1,145
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
May. 1, 2016 06:00 PM EDT Reads: 807
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
May. 1, 2016 05:00 PM EDT Reads: 1,009
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
May. 1, 2016 04:30 PM EDT Reads: 1,474
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
May. 1, 2016 04:00 PM EDT Reads: 925
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
May. 1, 2016 03:15 PM EDT Reads: 1,028
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
May. 1, 2016 01:45 PM EDT Reads: 1,229
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
May. 1, 2016 01:30 PM EDT Reads: 1,570
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
May. 1, 2016 01:30 PM EDT Reads: 810
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
May. 1, 2016 01:00 PM EDT Reads: 1,745
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
May. 1, 2016 12:45 PM EDT Reads: 815